June 25th 2025
Marketed as Orlynvah, oral sulopenem from Iterum Therapeutics was FDA approved last fall for uncomplicated urinary tract infections (uUTIs), and has shown efficacy against infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control
October 7, 2025
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
Debating the Value of Incorporating Antibiotic Stewardship Principles Into Infection Guidelines
January 20th 2025Significant value can be offered through the incorporation of stewardship concepts into infection guidelines, but we must also address the risk and challenges it may impose on health care systems.
Read More
The Slow-Moving Antimicrobial Resistance Train is Picking-up Morbidity and Mortality Steam
December 20th 2024Resistance is expected to worsen significantly, but can a combination of both ground-level clinician stewardship actions as well as systemic reforms such as the Pasteur Act at least slow down the train?
Read More